CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cell Therapeutics plans to initiate two clinical trials evaluating the use of the non-Hodgkin's B-cell lymphoma drug Zevalin (ibritumomab tiuxetan) in front-line lymphoma settings to drive revenues of the product after acquiring it from Biogen Idec. The company announced plans to buy Zevalin for $30 million in up-front and milestone payments Aug. 16